



CONSENSUS DOCUMENT

# [Translated article] Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

F.J. Navarro-Triviño<sup>a</sup>, L. Borrego<sup>b,\*</sup>, J.F. Silvestre-Salvador<sup>c</sup>, P. Mercader-García<sup>d</sup>,  
A.M. Giménez-Arnau<sup>e</sup>, F.J. Ortiz-de Frutos<sup>f</sup>, T. Sanz-Sánchez<sup>g</sup>, G. Melé-Ninot<sup>h</sup>,  
A. Sánchez-Gilo<sup>i</sup>, V. Zaragoza-Ninet<sup>j</sup>, E. Serra-Baldrich<sup>k</sup>, J. Miquel-Miquel<sup>l</sup>,  
S. Córdoba-Guijarro<sup>m</sup>, M. Rodríguez-Serna<sup>n</sup>, I. Ruíz-González<sup>o</sup>,  
J.M. Carrascosa-Carrillo<sup>p</sup>, E. Gómez-de la Fuente<sup>q</sup>, M.A. Pastor-Nieto<sup>r</sup>,  
F. Heras-Mendoza<sup>r</sup>, R. González-Pérez<sup>s</sup>, P. Sánchez-Pedreño Guillén<sup>t</sup>,  
J. Sánchez-Pérez<sup>u</sup>, M.E. Gatica-Ortega<sup>v</sup>, V. Fernández-Redondo<sup>w</sup>,  
M. Hervella-Garcés<sup>x</sup>, P. Manrique-Martínez<sup>y</sup>, D. Guimaraens-Juanena<sup>z</sup>,  
J. García-Gavín<sup>aa</sup>, E. Giménez-Arnau<sup>ab</sup>, I. Figueras-Nart<sup>ac</sup>, L. Curto-Barredo<sup>ad</sup>,  
J.C. Armario-Hita<sup>ae</sup>

- <sup>a</sup> Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, Spain
- <sup>b</sup> Servicio de Dermatología, Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
- <sup>c</sup> Servicio de Dermatología, Hospital Universitario Dr. Balmi, Alicante, Spain
- <sup>d</sup> Servicio de Dermatología, Hospital Universitario José María Morales Meseguer, Murcia, Spain
- <sup>e</sup> Servicio de Dermatología, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain
- <sup>f</sup> Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain
- <sup>g</sup> Servicio de Dermatología, Hospital Universitario Infanta Sofía, Madrid, Spain
- <sup>h</sup> Servicio de Dermatología, Hospital Universitari Sagrar Cor, Grupo Quironsalud, Barcelona, Spain
- <sup>i</sup> Servicio de Dermatología, Hospital Universitario Rey Juan Carlos, Madrid, Spain
- <sup>j</sup> Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain
- <sup>k</sup> Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- <sup>l</sup> Servicio de Dermatología, Hospital Universitario Arnau de Vilanova, Valencia, Spain
- <sup>m</sup> Servicio de Dermatología, Hospital Universitario de Fuenlabrada, Madrid, Spain
- <sup>n</sup> Servicio de Dermatología, Hospital Universitario La Fe, Valencia, Spain
- <sup>o</sup> Servicio de Dermatología, Complejo Asistencial Universitario de León, León, Spain
- <sup>p</sup> Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
- <sup>q</sup> Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, Spain
- <sup>r</sup> Servicio de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- <sup>s</sup> Servicio de Dermatología, Hospital Universitario Áraba, Universidad del País Vasco, Vitoria, Álava, Spain
- <sup>t</sup> Servicio de Dermatología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- <sup>u</sup> Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain

\* Corresponding author.  
E-mail address: leopoldo.borrego@ulpgc.es (L. Borrego).

<https://doi.org/10.1016/j.ad.2024.05.018>  
0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: F.J. Navarro-Triviño, L. Borrego, J.F. Silvestre-Salvador et al., [Translated article] Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC), ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.05.018>

<sup>v</sup> Servicio de Dermatología, Complejo Hospitalario Universitario de Toledo, Toledo, Spain

<sup>w</sup> Servicio de Dermatología, Complejo Hospitalario Universitario de Santiago, Universidad de Santiago, Santiago de Compostela, La Coruña, Spain

<sup>x</sup> Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

<sup>y</sup> Servicio de Dermatología, Hospital Universitario Galdakao-Usansolo, Galdakao, Vizcaya, Spain

<sup>z</sup> INSHT, Ministerio de Empleo y Seguridad Social, Madrid, Spain

<sup>aa</sup> Gavín Dermatologos, Vigo, Pontevedra, Spain

<sup>ab</sup> Institut de Chimie CNRS UMR 7177, University of Strasbourg, Strasbourg, France

<sup>ac</sup> Servicio de Dermatología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

<sup>ad</sup> Servicio de Dermatología, Hospital del Mar, Barcelona, Spain

<sup>ae</sup> Servicio de Dermatología, Hospital Universitario Puerto Real, Universidad de Cádiz, Cádiz, Spain

Received 12 March 2024; accepted 19 March 2024

## KEYWORDS

Consensus;  
Allergic contact  
dermatitis;  
Patch testing;  
GEIDAC

## PALABRAS CLAVE

Consenso;  
Dermatitis alérgica  
de contacto;  
Pruebas epicutáneas;  
GEIDAC

**Abstract:** After the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish Standard Series patch testing. Hydroxyethyl methacrylate (2% pet.), textile dye mixt (6.6% pet.), linalool hydroperoxide (1% pet.), and limonene hydroperoxide (0.3% pet.) were, then, added to the series that agreed upon in 2016. Ethyldiamine and phenoxyethanol were excluded. Methylidibromoglutaronitrile, the mixture of sesquiterpene lactones, and hydroxyisohexyl 3-cyclohexene (Lyril) were also added to the extended Spanish series of 2022.

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Actualización de la batería estándar y batería ampliada de pruebas alérgicas de contacto por el Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC)

**Resumen** En la reunión de consenso celebrada por el Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea en octubre del 2021 se estableció la composición actualizada de la batería estándar española de pruebas epicutáneas. A la batería consensuada en 2016 se añaden hidroxietilmetacrilato (2% vas.), mezcla colorante textil (6,6% vas.), hidroperóxido de linalool (1% vas.) e hidroperóxido de limoneno (0,3% vas.). Se excluyen la etilidiamina y el fenoxietanol. El metildibromoglutaronitrilo, la mezcla de lactonas sesquiterpénicas y el hidroxioisohexil 3-ciclohexeno (Lyril) pasan a la batería española ampliada 2022.

© 2024 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

## Introduction

The diagnosis of allergic contact dermatitis (ACD) is established after performing the necessary patch testing.<sup>1</sup> All patients undergoing such testing should be patched with the Spanish Standard Series (SSS)<sup>2-4</sup> and, based on the clinical pattern they present, relevant additional batteries should be used. Depending on the peculiarities of each center, the standard series should detect 77% up to 90% of positivities.<sup>5</sup>

AEDV Spanish Research Working Group on Contact Dermatitis and Cutaneous Immunoallergy (GEIDAC) is responsible for updating the SSB. In October 2021, GEIDAC met to agree on an update of the 2016 SSB. In the SSB review, and subsequently in the European standard review, the GEIDAC proposed that allergens should be included based on prospectively studied data.<sup>3,6,7</sup> This means that besides the

SSB, there is a group of allergens eligible to be included in the SSB, which have already been listed in the Spanish Extended Series (SES).<sup>1,3,8</sup> The two series are dynamic proposals, with updates recommended for expanded standard batteries nearly every 2 years, and national batteries every 5 to 10 years.

By criterion of authority, an allergen should be listed in a national standard series if it is responsible for 0.5% to 1% sensitization of unselected patients who underwent patch testing.<sup>1</sup> Although this is the most important criterion, its inclusion should also be evaluated based on specific clinical areas (especially occupational and geographical), if it is emerging in neighboring countries, and practical aspects should, also, be taken into consideration such as back surface limitation. Although strictly, the inclusion criterion should be relevant at the present time, subjectivity

**Table 1** Patients evaluated with the 2016 Spanish Standard Series (SSS).

Allergens	Patients patched (n)	Sensitization Positives (n)	%	95%CI	Present relevance (n)	%	95%CI	Tests needed for present relevance
Nickel sulfate	6875	1.708	24.8	23.69-26.05	355	5.16	4.65-5.73	19
Wool alcohols (lanolin)	6870	50	0.7	0.55-0.96	34	0.49	0.35-0.69	202
Neomycin sulfate	6869	72	1.0	0.83-1.32	18	0.26	0.17-0.42	382
Potassium dichromate	6870	239	3.5	3.06-3.95	121	1.76	1.47-2.10	57
Cain mix	6789	78	1.1	0.92-1.43	16	0.24	0.14-0.38	424
Fragrance mix I	6870	312	4.5	4.06-5.07	171	2.49	2.14-2.89	40
Colophony	6872	110	1.6	1.33-1.93	49	0.71	0.54-0.94	140
Paraben mix	6881	33	0.5	0.34-0.67	16	0.23	0.14-0.38	430
Peru balsam	6874	234	3.4	2.99-3.87	94	1.37	1.12-1.67	73
Ethylenediamine dihydrochloride	6818	70	1.0	0.81-1.30	21	0.31	0.20-0.47	325
Cobalt chloride	6875	351	5.1	4.60-5.67	84	1.22	0.99-1.51	82
P-tert-butylphenol formaldehyde	6871	116	1.7	1.41-2.03	26	0.38	0.26-0.56	264
Epoxy resin	6871	70	1.0	0.81-1.29	21	0.31	0.20-0.47	327
Carbam mix	6789	128	1.9	1.59-2.24	72	1.06	0.84-1.34	94
IPPD/black rubber mix	6873	66	1.0	0.75-1.22	25	0.36	0.25-0.54	275
MCI/MI	5589	272	4.9	4.32-5.48	188	3.36	2.92-3.88	30
Quaternium-15	6886	69	1.0	0.79-1.27	40	0.58	0.43-0.79	172
Methyldibromo glutaronitrile	6883	176	2.6	2.21-2.96	19	0.28	0.18-0.43	362
paraphenylenediamine	6872	296	4.3	3.84-4.83	174	2.53	2.18-2.94	39
Formaldehyde 2%	5819	170	2.9	2.51-3.40	82	1.41	1.13-1.75	71
Mercapto mix	6869	28	0.4	0.28-0.59	19	0.28	0.18-0.43	362
Thiuram mix	6868	120	1.7	1.46-2.09	89	1.30	1.05-1.60	77
Diazolidinyl urea (Germall II)	6886	34	0.5	0.35-0.69	17	0.25	0.15-0.40	405
Tixocortol-21-pivalate	6874	32	0.5	0.33-0.66	16	0.23	0.14-0.38	430
Imidazolidinyl urea (Germall 115)	6887	27	0.4	0.27-0.57	10	0.15	0.	
Budesonide	6876	60	0.9%	0.68-1.12	31	0.45%	0.32-0.64	222
Mercaptobenzothiazole	6871	32	0.5%	0.33-0.66	20	0.29%	0.19-0.45	344
Methylisothiazolinone	6319	516	8.2%	7.49-8.90	400	6.33%	5.74-6.98	16
Lactone mix	6187	13	0.2%	0.12-0.36	6	0.10%	0.04-0.22	1,031
Fragrance mix II	6314	232	3.7%	3.23-4.18	154	2.44%	2.08-2.86	41
Lyrall	6308	58	0.9%	0.71-1.19	36	0.57%	0.41-0.79	175
Phenoxyethanol	6308	6	0.1%	0.04-0.21	2	0.03%	0.01-0.13	3116

Consensus document on the 2022 Spanish Standard Series (SSS).

**Table 2** Patients patch tested with the candidate allergen series or 2019 Spanish Extended Series (SES).

Allergens	Patched Patients (n)	Sensitization Positives (n)	%	95%CI	Present relevance (n)	%	Patches needed for present relevance (n)
<b>Chemotechnique and allergaze</b>							
<i>Allergens included in the European Standard Series candidates for the Spanish Standard Series</i>							
2-hydroxyethyl methacrylate (HEMA)	1884	69	3.66	2.90-4.61%	48	2.50	39
Textile mix	1828	59	3.13	2.43-4.01%	17	0.90	108
Propolis	1885	26	1.38	0.94-2.02%	5	0.27	377
<i>Allergens included in the Spanish Standard Series eligible for the European Standard Series</i>							
Diazolidinyl urea	1608	4	0.25	0.09-0.66%	3	0.19	536
Imidazolidinyl urea	1609	3	0.19	0.06-0.8%	1	0.06	1609
<i>Allergens candidates for the European and Spanish Standard Series</i>							
Linalool hydroperoxide (1% vas)	1813	84	4.43	3.59-5.45%	51	2.70	36
Linalool hydroperoxide (0.3% vas)	1640	57	3.36	2.60-4.33%	35	2.10	47
Limonene hydroperoxide (0.3% vas)	1830	60	3.17	2.47-4.07%	37	2.00	49
Limonene hydroperoxide (0.2% vas)	1651	24	1.43	0.96-2.13%	15	0.90	110
Benzisothiazolinone	1810	66	3.52	2.77-4.45%	18	0.96	101
Octylisothiazolinone	1874	11	0.58	0.32-1.05%	1	0.05	1874
Sodium metabisulfite	1850	35	1.89	1.34-2.58%	5	0.27	370
2-bromo-2-nitropropane-1,3-diol (bronopol)	1712	13	0.76	0.44-1.29%	2	0.12	856
Compound mix II	1642	7	0.43	0.20-0.89%	2	0.12	821
Decyl glucoside	1869	15	0.80	0.48-1.32%	6	0.32	312
Lauryl glucoside	1874	6	0.32	0.14-0.71%	1	0.05	1874
<i>TRUE-Test</i>							
Diazolidinyl urea	3065	14	0.46	0.27-0.77%	6	0.20	511
Imidazolidinyl urea	3065	13	0.42	0.25-0.73%	5	0.16	613
Bronopol	3065	20	0.65	0.42-1.01%	12	0.39	255

Data already published. Obtained from Hernández-Fernández et al.<sup>8</sup>.

in assessing this relevance causes this parameter to be used secondarily to the overall sensitization frequency.<sup>1</sup> The most significant piece of information regarding present relevance is the number of patched patients required to achieve this relevance,<sup>9</sup> as shown in [tables 1 and 2](#).

Progress in digital technology has had an impact on ACD. In 2018, a multicenter registry supported by AEDV Research Unit was created by GEIDAC members, and is the data source in this document.<sup>10</sup>

## Material and methods

The structure of the Spanish Registry of Research in Allergic and Contact Dermatitis (REIDAC) has been previously described.<sup>10</sup> Data from the SSB were obtained from the general form ([table 1](#)). Afterwards, a form was created for candidate allergens of the ESB ([table 2](#)). Data from the SSB were obtained from the beginning of the registry (June 1<sup>st</sup>, 2018) through December 2020. Data from the ESB were collected from January 1<sup>st</sup>, 2019 through December 31<sup>st</sup>, 2020. In October 2021, a meeting was held to establish the new SSB and ESB. Previously, the working group completed an online survey for the initial assessment of permanence, exclusion, or inclusion of each allergen in the proposed series.

## Results

A total of 6870 patients were evaluated with the 2016 SSB and 1890 with the ESB. The results are shown in [tables 1 and 2](#).

## Consensus meeting

For consistency with the European standard and expanded series, allergens from the Spanish batteries must include allergens from both European batteries. For operational criteria, it was agreed that the SSB should list nearly 30 allergens. Similarly, the concentration of cain mix was updated according to the European standard series, including 5% benzocaine<sup>11</sup> ([tables 3 and 4](#)).

Considering that the dilution support of the allergens is expressed in [table 3](#), the criterion for allowing the TRUE-Test® (Thin-layer Rapid Use Epicutaneous-Test, SmartPractice Denmark ApS, Hillerød, Denmark) as support for the ESB was kept except for the concentrations of chloromethylisothiazolinone-methylisothiazolinone and formaldehyde.<sup>12</sup> For clinicians still using the TRUE Test®, it is essential to expand the patches studied according to [Table 5](#).

The most controversial allergen was methyl dibromo glutaronitrile because, although the sensitization rate justified that it should stay, the relevance of positivity is quite questionable.<sup>13,14</sup> Given the need to maintain active surveillance on the molecule, it was decided to exclude it from the SSB and list it in the ESB.<sup>15,16</sup> Lyrál—individually patched and included in fragrance mix II—presents very low sensitization rates and most likely covered by fragrance mix II, and has been banned by the European legislation. Although Lyrál has been removed from the SSB it temporarily remains

**Table 3** 2022 Spanish Standard Series (SSS).

GEIDAC: Spanish Standard Series 2022	
1 Nickel sulfate	5.0% vas
2 Wool alcohols (lanolin)	30.0% vas
3 Neomycin sulfate	20.0% vas
4 Potassium dichromate (chromium salts)	0.5% vas
5 Cain mix	10% vas
6 Fragrance mix I	8.0% vas
7 Colophony	20.0% vas
8 Paraben mix	16.0% vas
9 Peru balsam	25.0% vas
10 Cobalt chloride (cobalt salts)	1.0% vas
11 p-tert-butylphenol formaldehyde resin	1.0% vas
12 Epoxy resin	3.0% vas
13 Carbam mix	0.1% vas
14 IPPD/black rubber mix	0.02% aq
15 MCI/MI	1.0% vas
16 Quaternium-15	1.0% vas
17 Paraphenylenediamine	2.0% aq
18 2% Formaldehyde	2.0% vas
19 Mercapto mix	1.0% vas
20 Thiuram mix	0.1% vas
21 Diazolidinyl urea (Germall II)	0.01% vas
22 Tixocortol-21-pivalate	2.0% vas
23 Imidazolidinyl urea (Germall 115)	0.2% aq
24 Budesonide	14.0% vas
25 Mercaptobenzothiazole	2.0% vas
26 Methylisothiazolinone	0.2% aq
27 Fragrance mix II	6.6% vas
28 Hydroxyethyl methacrylate	1.0% vas
29 Textile dye mix	0.3% vas
30 Linalool hydroperoxide	
31 Limonene hydroperoxide	

in the ESB<sup>17,18</sup> for consistency with the European series. Ethylenediamine<sup>3,4,19–22</sup> and phenoxyethanol—already controversial in the 2012 meeting—were removed from the SSB.<sup>3,23</sup>

In GEIDAC administrative meeting of September 2023, a new ESB was approved for use in centers starting January 1<sup>st</sup>, 2024 ([table 4](#)).

## Discussion

If we compare the results of the SSB with those previously published,<sup>2,34</sup> it is surprising that, except for the exchange of methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) for methylisothiazolinone (MI), very few changes have been reported regarding the sensitization frequency of allergens.<sup>8,24</sup>

## Metal

The group of metals are the most frequent sensitizers in all published series.<sup>25</sup> Nickel sulfate has a high sensitization rate (24.8%). Nonetheless, a slight decrease has been reported in other European countries.<sup>26</sup> Cobalt chloride continues to show sensitization rates of up to 4.87%.<sup>24</sup> Contact sources justify both the high sensitization rates reported



**Table 4** Proposals for Spanish Extended Series for 2022 and 2024.

Spanish Expanded Standard Series for 2022	Spanish Expanded Standard Series for 2024
1 Methyl dibromo glutaronitrile 0.5% vas	1 Methyl dibromo glutaronitrile 0.5% vas
2 Lactone mix 0.1% vas	2 Lactone mix 0.1% vas
3 Hydroxyisohexyl 3-cyclohexene carboxaldehyde 5% vas	3 Hydroxyisohexyl 3-cyclohexene carboxaldehyde 5% vas
4 Propolis 10% vas	4 Propolis 10% vas
5 Sodium metabisulfite 1% vas	5 Sodium metabisulfite 1% vas
6 2-bromo-2-nitropropane-1,3-diol (bronopol) 0.5% vas	6 2-bromo-2-nitropropane-1,3-diol (bronopol) 0.5% vas
7 Compound mix 2.5% vas	7 Compound mix 5% vas
8 Linalool hydroperoxide 0.5% vas	8 Linalool hydroperoxide 0.5% vas
9 Limonene hydroperoxide 0.2% vas	9 Limonene hydroperoxide 0.2% vas
10 Benzisothiazolinone 0.1% vas	10 Benzisothiazolinone 0.1% vas
11 Octyl isothiazolinone 0.1% vas	11 Octyl isothiazolinone 0.1% vas
12 Decyl glucoside 5% vas	12 Decyl glucoside 5% vas
13 Lauril polyglucoside 3% vas	13 Sorbitan sesquioleate 20% vas
14 Ethylenediamine dihydrochloride 1% vas	14 Sorbitan monooleate 5% vas
15 Clobetasol propionate 0.1% ethanol	
16 Clobetasol propionate 1% vaseline	
17 Propylene glycol 100%	
18 Propylene glycol 30% water	
19 Shellac 20% ethanol	
20 Galate mix 1% vas	
21 Octyl gallate 0.25% vas	
22 Dodecyl gallate 0.25% vas	
23 Propyl gallate 1% vas	

**Table 5** Allergens that need to be added to the TRUE-Test® to complete the 2022 Spanish Standard Series (SSS).

MCI/MI <sup>a</sup> 0.02% aq
Formaldehyde 2% <sup>a</sup> 2.0% aq
Methylisothiazolinone 0.2% aq
Fragrance mix II 14.0% vas
Hydroxyethyl methacrylate 2.0% vas
Textile dye mix 6.6% vas
Linalool hydroperoxide 1.0% vas
Limonene hydroperoxide 0.3% vas

<sup>a</sup> Inadequate concentrations in TRUE-Test®. The remaining allergens are not present.

and the possibility of co-sensitization due to common exposure in the workplace, jewelry, or tattoos.<sup>27,28</sup> Potassium dichromate has undergone some nonsignificant variation in its frequency, possibly due to legislative changes in its main contact source, cement.<sup>24,29</sup>

## Biocides

Due to exposure risk, biocides form one of the most important groups since they are present in both industrial and cosmetic products. The latest sensitization data to MI from 2022 provide sensitization rates of 7.08% vs 4.49% for the MCI/MI mixture.<sup>24</sup> In 2018, MI showed a sensitization rate of up to 8.55%, indicating that, although high, there is a downward trend in sensitization rates.<sup>24</sup>

There are two other 2-isothiazolinones under study: benzothiazolinone (BIT) and octylisothiazolinone (OIT). Both are prohibited in cosmetics. The main exposure source is

industrial products, detergents, and paints.<sup>29,30-33</sup> BIT sensitization data in 2022 was 3.5%,<sup>8</sup> which justifies its possible inclusion in the SSB. Due to the low relevance of positive tests, it was decided to keep it in the ESB. The OIT sensitization rate was very low, remaining in the ESB for consistency with the European battery only<sup>8</sup> (tables 3 and 4).

Formaldehyde and formaldehyde releasers represent the second most important group of biocides.<sup>31</sup> After changing patch concentration to 2% formaldehyde in water in 2014, many more cases of ACD can be established.<sup>12,32,33</sup> Recent positivity data to formaldehyde reached 2.9% in the latest REIDAC analysis. Compared with the TRUE-Test, the latter detects only one-third of sensitization cases.<sup>34</sup> Of note that formaldehyde is not a good marker for sensitization to formaldehyde releasers.<sup>35</sup> Although quaternium-15 (formaldehyde releaser) has been removed from the European series, it is still in the SSB with a positivity rate of 1%.<sup>36</sup> More for historical reasons than justified by its sensitization rates, the SSB still lists imidazolidinyl urea (0.4% positivity) and diazolidinyl urea (0.5% positivity), while bronopol can be found in the ESB<sup>8</sup> even though the prevalence of positives is similar vs the other 2 above-mentioned formaldehyde releasers.<sup>37</sup>

Parabens are esters of p-hydroxybenzoic acid used as preservatives in cosmetic products and drugs. Although they have been identified as responsible for certain carcinogenic risk,<sup>38</sup> they are still unrestrictedly being used. The mixture consists of 4 parabens (methyl p-hydroxybenzoate 4%, propyl p-hydroxybenzoate 4%, butyl p-hydroxybenzoate 4%, and ethyl p-hydroxybenzoate 4%). One of the SSB suppliers only lists ethylparaben. Although positivity rate is only 0.5%, parabens are being kept in the SSB.

During the study period, the sensitization rate of sodium metabisulfite was monitored. In Europe, a 3.75% sensitization rate has been reported,<sup>6</sup> while in Spain it has dropped down to 2.1%.<sup>39</sup> The percentage of present relevance according to European data is 50% (25% in the Spanish series), indicating the need to better understand the sources of sensitization, remaining in the ESB.<sup>40-42</sup>

## Fragrances

Sensitization rates to the main fragrance markers (fragrance mix I and II), and Peru balsam (*Myroxylon pereirae* resin), continue to be high. Sensitization rates to fragrance mix I, fragrance mix II, and Peru balsam were 4.1%, 3.41%, and 3.22%, respectively.<sup>24</sup> In 2021, the sensitization rate to specific allergens in the fragrance series was published, with geraniol, isoeugenol, and *Evernia prunastri* being the most common allergens of all.<sup>43</sup> Citral and lylal were more common in cases of professional origin.<sup>43</sup>

None of the 3 above-mentioned fragrance markers lists the terpenoids linalool and limonene or their hydroperoxides (considered responsible for sensitization).<sup>44</sup> Given the high positivity rate (4.6% for linalool and 3.3% for limonene) and the established positive relevance to both allergens (61.4% for linalool and 61.7% for limonene), they have been added to the SSB.<sup>8</sup> Interpreting the reactions to these 2 allergens can be difficult as they can be considered irritants,<sup>45,46</sup> which is why the 0.5% concentration for linalool hydroperoxide and the 0.2% for limonene hydroperoxide in the ESB is still under consideration.

## Dyes/paraphenylenediamine

Nationwide, paraphenylenediamine (PPD) continues to be the go-to sensitizer in dyes.<sup>24</sup> The cause of sensitization mainly depends on the patient's age.<sup>47</sup> In children, it is associated with contact with adulterated henna tattoos,<sup>48</sup> while middle-aged individuals, it has been associated with the hairdressing career, and subsequently with hair dye users.<sup>46</sup>

The textile mixture was listed as a candidate allergen back in the 2019 ESB with a sensitization rate in 2022 of up to 3.1%,<sup>8,24</sup> which justifies its addition to the SSB8. This mix allows for the study of generalized or flexural ACD of clothing origin, which should be taken into consideration in the differential diagnosis with atopic dermatitis.<sup>32,49</sup>

## Plants

This is a very heterogeneous and difficult group to manage. The mix of sesquiterpene lactones and composite mixture are internationally recognized markers. For consistency with the European series, the two mixtures have been included in the ESB. The composite mixture (*Tanacetum vulgare*, *Arnica montana*, *Parthenolide*, *Chamomilla romana*, *Chamomilla recutita*, and *Tanacetum millefolium*) has a 2.31% sensitization rate in Europe<sup>26</sup> and a 0.43% sensitization rate in Spain.<sup>8</sup> In the last European review, it was decided to increase its concentration from 2.5% up to 5%.<sup>7,50,51</sup>

Other allergens in the SSB, such as colophony, propolis, or fragrances, could be less specific markers of plant sensitization.

## Adhesives/glues

Epoxy resin continues to be considered an occupational sensitization marker,<sup>52</sup> although there has been an increase in recreational cases,<sup>53-55</sup> remaining in the SSB. The 4-tert-butylphenol formaldehyde resin is a good marker,<sup>56</sup> especially for foot dermatitis.<sup>57</sup> In recent years, and in relation to the sensitization epidemic to acrylates in users and professionals of nail cosmetics, hydroxyethyl methacrylate (HEMA) has been added to both the European standard series and the SSB. Other sources of sensitization are inks, lacquers, adhesives, and dental and medical materials. The sensitization rate for HEMA was 3.66%, which justifies its inclusion in the SSB, although the most recent data reveal a higher sensitization rate.<sup>24</sup>

## Vulcanization accelerators

Considering chronic hand eczema as the main reason for patient referral to Contact Dermatitis units, this group of allergens is a must in the SSB to rule out sensitization to gloves used as a protective measure. The thiuram mixture remains in the European series, but unlike these, in Spain, carbamate mixture remains (relevant sensitization rate at 1.9%).<sup>24</sup> The positivity rate for the mercapto mixture is 0.4%, and for mercaptobenzothiazole, 0.5%. The important thing is that the two of them associate a positive relevance > 60%, which keeps them in the SSB.

## Vehicles and emulsifiers

Glucosides are non-ionic surfactants that show high sensitization in studies conducted in the United States.<sup>58</sup> This rate is lower in Europe and even lower in the Spanish population.<sup>59</sup> Decyl glucoside remains in the ESB for consistency with the European battery.

The rise of biocosmetics has justified interest in propolis. This hapten remains listed in the European standard series since 2019.<sup>60</sup> The sensitization rate in Central Europe from 2015 through 2018 was 3.94%,<sup>61</sup> while in Spain it stands at 1.38%.<sup>8</sup> Due to geographical heterogeneity in its sensitization,<sup>62</sup> and its low—though non-negligible—sensitization rate in Spain, its presence in the ESB is justified to determine the areas where it is truly relevant.

Propylene glycol is an aliphatic alcohol, which is widely used in the industrial, agri-food, health care, and cosmetic fields. It presents both irritative and allergic reactions, with the optimal concentration for use in patches still to be elucidated. Due to its ubiquity, it was listed as a candidate allergen back in the 2022 ESB at concentrations of 30% and 100%.

The use of shellac, or shellac gum, has increased in the context of "natural" molecules. It is the purified form of the resin produced by the female bug of the *kerria lacca*. It is used in the wood industry, advanced technology, printing,

cosmetics, food, and pharmaceuticals. The publication of cases in Spain related to the food industry and the use of cosmetics suggested its study in the 2023 ESB.<sup>63-65</sup>

Sorbitan oleate and sorbitan sesquioleate were listed in the expanded European series in July 2023.<sup>7</sup> These haptens are part of the vehicles used in other allergens, such as fragrances, Peru balsam, HEMA, and sunscreens at wholesale purchasing level.<sup>66</sup> The need for discriminating allergen sensitization or their vehicle has motivated their addition to the 2024 ESB.

## Drugs

In drug-induced contact dermatitis, the first diagnostic suspicion should be directed towards excipients, including fragrances and Peru balsam. As active ingredients, neomycin stands out, which, although with low sensitization rates, is still considered an allergen used in creams for the management of wounds, ulcers, and burns.

Within the European and Spanish Standard Series, topical corticosteroids are represented by tixocortol pivalate and budesonide. At the meeting, the need for a marker of Group III corticosteroids, from Baeck's classification, was reported, so clobetasol propionate was proposed to be listed in the 2022 ESB.<sup>67</sup>

Hand dermatitis and intolerance to cosmetics are the 2 most important reasons to seek medical attention in Contact Dermatitis unit, and without detriment to the need for specific batteries, the SSB must cover the higher number of patients treated.<sup>5</sup> Since both the hands and the facial region are the main affected areas, the SSB must include the main allergens involved in these locations. Considering the above-mentioned premise, metals, biocides, fragrances, and vulcanization accelerators lead the SSB list.

## Conclusions

The SSB is updated and should be used in all patients undergoing contact patch testing nationwide from January 2022 (Table 3).

## Funding

The REIDAC is sponsored by the Spanish Academy of Dermatology and Venereology (Fundación Piel Sana), and has received funding from the Spanish Agency of Medicines and Medical Devices (<https://www.boe.es/boe/dias/2022/04/11/pdfs/BOE-A-2022-5975.pdf>) and Sanofi®. REIDAC sponsors did not intervene in the proposal for preparation, design, data mining, analysis and interpretation, drafting, revision, approval, or logistical support associated with the present manuscript.

## Acknowledgments

The authors wish to express their gratitude to Dr. Ignacio Garcia, Dr. Miguel Angel Descalzo, and Dr. Marina de Vega from AEDV Research Unit for their invaluable contribution to the meticulous exploitation and maintenance of the registry.

## References

1. Bruze M, Condé-Salazar L, Goossens A, Kanerva L, White IR. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. *Contact Dermatitis*. 1999;41:241–50.
2. Camarasa JM. First epidemiological study of contact dermatitis in Spain-1977. Spanish Contact Dermatitis Research Group. *Acta Derm Venereol Suppl (Stockh)*. 1979;59:33–7.
3. Hervella-Garcés M, García-Gavín J, Silvestre-Salvador JF. The Spanish standard patch test series: 2016 update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). *Actas Dermosifiliogr*. 2016;107:559–66.
4. García-Bravo B, Conde-Salazar L, De la Cuadra J, Fernández-Redondo V, Fernández-Vozmediano JM, Guimaraens D, et al. Estudio epidemiológico de la dermatitis alérgica de contacto en España (2001). *Actas Dermosifiliogr*. 2004;95:14–24.
5. Menné T, Dooms-Goossens A, Wahlberg JE, White IR, Shaw S. How large a proportion of contact sensitivities are diagnosed with the European standard series? *Contact Dermatitis*. 1992;26:201–2.
6. Uter W, Wilkinson SM, Aerts O, Bauer A, Borrego L, Buhl T, et al. European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCAA and the EBSB working groups of the ESCD, and the GEIDACC. *Contact Dermatitis*. 2022;86:379–89.
7. Wilkinson SM, Gonçalo M, Aerts O, Badulici S, Dickel H, Gallo R, et al. The European baseline series and recommended additions: 2023. *Contact Dermatitis*. 2023;88:87–92.
8. Hernández-Fernández CP, Mercader-García P, Silvestre Salvador JF, Sánchez Pérez J, Fernández Redondo V, Miquel Miquel FJ, et al. Alérgenos candidatos para ser incluidos en la serie estándar española a partir de los datos del Registro Español de Dermatitis de Contacto. *Actas Dermosifiliogr*. 2021;112:798–805.
9. García-Gavín J, Mercader P, Descalzo MA, Garcia-Doval I, Silvestre JF, Sánchez-Pérez J, et al. Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series. *Br J Dermatol*. 2020;183:391–3.
10. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. *Contact Dermatitis*. 2015;73:195–221.
11. Uter W, Worm M, Brans R, Wagner N, Bauer A, Geier J; Information Network of Departments of Dermatology (IVDK). Patch test results with caine mix III and its three constituents in consecutive patients of the IVDK. *Contact Dermatitis*. 2021;84:481–3.
12. Sanz-Sánchez T, Heras Mendaza F, González Pérez R, Córdoba Guijarro S, Gatica-Ortega ME, Fernández Redondo V, et al. Comparative study of formaldehyde 2% in aqueous solution vs. TRUE Test in detecting formaldehyde sensitization. *Contact Dermatitis*. 2021;85:358–9.
13. Luis-Gronau C, Cruzval-O'Reilly E, Lugo-Somolinos A. Methylidibromoglutaronitrile: increased incidence, but lacks clinical relevance. *Dermatitis*. 32: e135-e136.
14. Filon FL, Bongiorno L, Prodi A, Rui F, Fortina AB, Corradin MT. Effectiveness of European Regulation on Euxyl K400 sensitization in Northeastern Italy from 1996 to 2012 and occupation. *Dermatitis*. 2017;28:327–8.
15. Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Gimenez-Arnau AM, Ruiz-Gonzalez I, et al. Should methylidibromo glutaronitrile continue to be used in the European baseline series? A REIDAC national cross-sectional study. *Contact Dermatitis*. 2021;85:572–7.
16. Leyden JJ, Klighman AM. Allergic contact dermatitis: Sex differences. *Contact Dermatitis*. 1977;3:333–6.



17. Stingeni L, Hansel K, Corazza M, Foti C, Schena D, Fabbrocini G, et al. Contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Italy: Prevalence, trend, and concordance with fragrance mix II. *Contact Dermatitis*. 2023;88:129–33.
18. Ahlström MG, Uter W, Ahlström MG, Johansen JD. Decrease of contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Europe prior to its ban and diagnostic value. *Contact Dermatitis*. 2021;84:419–22.
19. Goossens A, Baret I, Swevers A. Allergic contact dermatitis caused by tetrahydroxypropyl ethylenediamine in cosmetic products. *Contact Dermatitis*. 2011;64:161–4.
20. Haddock EES, Shaw DW. Allergic contact dermatitis to the ethylenediamine component of aminophylline in a neck cream. *Dermatitis*. 2021;32:e73–4.
21. Blomberg M, Jørgensen CCL, Bregnhøj A, Ahrensboell-Friis U, Zachariae C, Sommerlund M, et al. Occupational allergic contact dermatitis caused by tetrahydroxypropyl ethylenediamine in hand disinfectants. *Contact Dermatitis*. 2022;87:114–6.
22. Dittmar D, Politeik K, Coenraads P-J, et al. Allergic contact dermatitis in two employees of an ethylene amine-producing factory. *Contact Dermatitis*. 2017;76:310–2.
23. Dréno B, Zuberbier T, Gelmetti C, Gontijo G, Marinovich M. Safety review of phenoxyethanol when used as a preservative in cosmetics. *J Eur Acad Dermatol Venereol*. 2019;33 Suppl 7:15–24.
24. Tous-Romero F, Borrego-Hernando L, García-Doval I, Mercader-García P, Silvestre-Salvador JF, Sánchez-Gilo A, et al. Four-year Epidemiological Surveillance of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy: Current Situation and Trends. *Actas Dermosifiliogr*. 2024;115:331–40.
25. Silverberg JI, Patel N, Warshaw EM, DeKoven JG, Bel-sito DV, Atwater AR, et al. Patch testing with nickel, cobalt, and chromium in patients with suspected allergic contact dermatitis. *Dermatitis*. 2023, <http://dx.doi.org/10.1089/derm.2023.0139>.
26. Uter W, Wilkinson SM, Aerts O, Bauer A, Borrego L, Brans R, et al. Patch test results with the European baseline series, 2019/20-Joint European results of the ESSCA and the EBS working groups of the ESCD, and the GEIDAC. *Contact Dermatitis*. 2022;87:343–55.
27. Schubert S, Kluger N, Schreiber I. Hypersensitivity to permanent tattoos: Literature summary and comprehensive review of patch tested tattoo patients 1997-2022. *Contact Dermatitis*. 2023;88:331–50.
28. Pesqué D, Borrego L, Zaragoza-Ninet V, Sanz-Sánchez T, Miquel-Miquel FJ, González-Pérez R, et al. Polysensitization in the Spanish Contact Dermatitis Registry (REIDAC): A 2019-2022 prospective study with cluster and network analysis. *Journal of the European Academy of Dermatology and Venereology*. DOI: 10.1111/jdv.19934.
29. Radillo L, Riosa F, Mauro M, Fortina AB, Corradin MT, Larese F. Contact dermatitis in construction workers in Northeastern Italian Patch Test Database Between 1996 and 2016. *Dermatitis*. 32: 381–387.
30. Geier J, Brans R, Weissshaar E, Wagner N, Szliska C, Heratizadeh A, et al. Contact sensitization to benzisothiazolinone: IVDK-data of the years 2002 to 2021. *Contact Dermatitis*. 2023;88:446–55.
31. Latorre N, Borrego L, Fernández-Redondo V, García-Bravo B, Giménez-Arnau AM, Sánchez J, et al. Patch testing with formaldehyde and formaldehyde-releasers: Multicentre study in Spain (2005-2009). *Contact Dermatitis*. 2011;65:286–92.
32. Isaksson M, Ryberg K, Goossens A, Bruze M. Recommendation to include a textile dye mix in the European baseline series. *Contact Dermatitis*. 2015;73:15–20.
33. Sanz-Sánchez T, Mercader García P, Silvestre Salvador JF, Heras Mendaza F, Gatica Ortega ME, González Pérez R, et al. Patch testing with formaldehyde 2% aq. —A multicenter study in Spain. *Contact Dermatitis*. 2019;81:458–9.
34. Sanz-Sánchez T, Heras Mendaza F, González Pérez R, Córdoba Guijarro S, Gatica-Ortega ME, Fernández Redondo V, et al. Comparative study of formaldehyde 2% in aqueous solution vs. TRUE Test in detecting formaldehyde sensitization. *Contact Dermatitis*. 2021;85:358–9.
35. Whitehouse H, Uter W, Geier J, Ballmer-Weber B, Bauer A, Cooper S, et al. Formaldehyde 2% is not a useful means of detecting allergy to formaldehyde releasers—results of the ESSCA network, 2015-2018. *Contact Dermatitis*. 2021;84:95–102.
36. Goossens A, Aerts O. Contact allergy to and allergic contact dermatitis from formaldehyde and formaldehyde releasers: A clinical review and update. *Contact Dermatitis*. 2022;87:20–7.
37. Sanz-Sánchez T, García PM, Silvestre Salvador JF, Mendaza FH, Guijarro SC, Pérez RG, et al. Contact allergy to formaldehyde releasers. Prospective multicenter study. *Contact Dermatitis*. 2020;82:173–5.
38. Al-Halaseh LK, Al-Adaileh S, Mbaideen A, Hajleh MNA, Al-Samydai A, Zakaraya ZZ, et al. Implication of parabens in cosmetics and cosmeceuticals: Advantages and limitations. *J Cosmet Dermatol*. 2022;21:3265–71.
39. Sanz-Sánchez T, Giménez-Arnau AM, Mercader-García P, González Pérez R, Zaragoza-Ninet V, Miquel-Miquel J, et al. Sodium metabisulfite a current low relevant allergen in Spain. *J Eur Acad Dermatol Venereol*. 2023, <http://dx.doi.org/10.1111/jdv.19702>.
40. Dendooven E, Darrigade AS, Foubert K, Pieters L, Lambert J, Goossens A, et al. The presence of sulfites in “natural rubber latex” and “synthetic” rubber gloves: An experimental pilot study. *Br J Dermatol*. 2020;182:1054–5.
41. Grosch E, Mahler V. Allergic contact dermatitis caused by a catheter system containing sodium metabisulfite. *Contact Dermatitis*. 2017;76:186–7.
42. Febriana SA, Jungbauer F, Soebono H, Coenraads PJ. Occupational allergic contact dermatitis and patch test results of leather workers at two Indonesian tanneries. *Contact Dermatitis*. 2012;67:277–83.
43. Sánchez-Pujol MJ, Docampo-Simón A, Mercader P, González-Pérez R, Hervella-Garcés M, Sanz-Sánchez T, et al. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. *Contact Dermatitis*. 2021;84:395–406.
44. Sukakul T, Bruze M, Mowitz M, Bergendorff O, Björk J, Dahlin J, et al. Patterns of simultaneous contact allergies in patients with contact sensitization to oxidised linalool and oxidised limonene. *Contact Dermatitis*. 2023, <http://dx.doi.org/10.1111/cod.14445>.
45. Llamas-Velasco M, Martos-Cabrera L, Butrón B, Sánchez-Pérez J. Escasa relevancia clínica en los parches positivos a limoneno o linalool en 247 pacientes consecutivos con eccema. *Actas Dermosifiliogr*. 2023, <http://dx.doi.org/10.1016/j.ad.2023.05.035>.
46. Almeida PJ, Borrego L, Limiñana JM. Age-related sensitization to p-phenylenediamine. *Contact Dermatitis*. 2011;64:172–4.
47. Sánchez-Pérez J, Descalzo-Gallego MA, Silvestre JF, Fernández-Redondo V, García-Gavín J, Ruiz-Gonzalez I, et al. Is p-phenylenediamine still a prevalent contact allergen in Spain? *Actas Dermosifiliogr*. 2020;111:47–52.
48. De Groot AC. Side-effects of henna and semi-permanent “black henna” tattoos: A full review. *Contact Dermatitis*. 2013;69:1–25.
49. Mobolaji-Lawal M, Nedorost S. The role of textiles in dermatitis: An update. *Curr Allergy Asthma Rep*. 2015;15:17.
50. Paulsen E, Andersen KE. Screening for Compositae contact sensitization with sesquiterpene lactones and Compositae mix 2.5% pet. *Contact Dermatitis*. 2019;81:368–73.

51. Paulsen E. The sesquiterpene lactone mix: A review of past, present and future aspects. *Contact Dermatitis*. 2023;89:434–41.
52. DeKoven JG, DeKoven BM, Warshaw EM, Mathias CGT, Taylor JS, Sasseville D, et al. Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016. *J Am Acad Dermatol*. 2022;86:782–90.
53. Temam I, Bauvin O, Boulard C. Epoxy resin, an emerging allergen in women? *Contact Dermatitis*. 2023;89:503–5.
54. Coco-Viloin M, Severino-Freire M, Giordano-Labadie F. Non-occupational allergic contact dermatitis from epoxy resin in children's games. *Contact Dermatitis*. 2023;88:232–4.
55. Dios-Guillán V, Matellanes-Palacios M, Bou-Boluda L, Fernández-Romero C, Miquel-Miquel J. Non-occupational, recreational epoxy resin contact allergy: Report of two cases. *Contact Dermatitis*. 2021, <http://dx.doi.org/10.1111/cod.13838>.
56. Lintu P, Soramäki I, Liippo J. Clinical relevance of p-tert-butylphenol-formaldehyde resin (PTBP-FR) contact allergy among general dermatology patients. *Contact Dermatitis*. 2020;83:324–6.
57. Rodríguez-Jiménez P, Descalzo MA, Giménez Arnau AM, Silvestre JF, García Gavín J, Fernández Redondo, et al. Trend of relevant contact allergens of the feet in Spain over a period of 10 years. *Contact Dermatitis*. 2020;82:211–7.
58. Warshaw EM, Xiong M, Atwater AR, DeKoven JG, Pratt MD, Maibach HI, et al. Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. *J Am Acad Dermatol*. 2022;87:1033–41.
59. Tous-Romero F, Giménez-Arnau AM, Sanz-Sánchez T, González Pérez R, Carrascosa-Carrillo JM, Zaragoza-Ninet V, et al. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. *J Eur Acad Dermatol Venereol*. 2023;37:e334–7.
60. Wilkinson M, Gonçalo M, Aerts O, Badulici S, Bennike NH, Bruynzeel D, et al. The European baseline series and recommended additions: 2019. *Contact Dermatitis*. 2019;80:1–4.
61. Uter W, Gefeller O, Mahler V, Geier J. Trends and current spectrum of contact allergy in Central Europe: Results of the Information Network of Departments of Dermatology (IVDK) 2007-2018. *Br J Dermatol*. 2020;183:857–65.
62. Nyman GSA, Giménez-Arnau AM, Grigaitiene J, Malinauskiene L, Paulsen E, Hagvall L. Corrigendum: Patch testing with propolis of different geographical origins in a baseline series. *Acta Derm Venereol*. 2022;102:adv00775.
63. Mercader-García P, Ruiz-Gonzalez I, Gonzalez-Perez R, Sanz-Sanchez T, Sanchez-Pérez J, Borrego L. Contact allergy to shellac. Retrospective cross-sectional study with data from the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy (REIDAC). *Actas Dermosifiliogr*. 2023;114:T377–81.
64. Mercader-García P. Occupational allergic contact dermatitis caused by shellac. *Contact Dermatitis*. 2022;86:557–9.
65. Navarro-Triviño FJ. Allergic contact dermatitis from shellac in an ecological hair spray occurring in a patient with frontal fibrosing alopecia. *Contact Dermatitis*. 2022;86:544–5.
66. Sukakul T, Bruze M, Mowitz M, Svedman C. Use of sorbitan sesquioleate in patch test preparations and patch testing with the substance-What do our results mean? *Contact Dermatitis*. 2023;88:134–8.
67. Mercader-García P, Pastor-Nieto MA, García-Doval I, Giménez-Arnau A, González-Pérez R, Fernández-Redondo V, et al. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study. *Contact Dermatitis*. 2018;78:76–82.